Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2009, Article ID 495863, 11 pages
http://dx.doi.org/10.1155/2009/495863
Review Article

Drug-Induced Hematologic Syndromes

Section of Hematology and Medical Oncology, Pennsylvania Hospital, Philadelphia, PA 19106, USA

Received 10 November 2008; Accepted 14 May 2009

Academic Editor: Estella M. Matutes

Copyright © 2009 David M. Mintzer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. A. Arndt and G. Garratty, “The changing spectrum of drug-induced immune hemolytic anemia,” Seminars in Hematology, vol. 42, no. 3, pp. 137–144, 2005. View at Publisher · View at Google Scholar
  2. S. T. Johnson, J. T. Fueger, and J. L. Gottschall, “One center's experience: the serology and drugs associated with drug-induced immune hemolytic anemia—a new paradigm,” Transfusion, vol. 47, no. 4, pp. 697–702, 2007. View at Publisher · View at Google Scholar · View at PubMed
  3. A. R. Gaines, “Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rho(D) immune globulin intravenous administration for immune thrombocytopenic purpura,” Blood, vol. 106, no. 5, pp. 1532–1537, 2005. View at Publisher · View at Google Scholar · View at PubMed
  4. G. Borthakur, S. O'Brien, W. G. Wierda et al., “Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab—incidence and predictors,” British Journal of Haematology, vol. 136, no. 6, pp. 800–805, 2007. View at Publisher · View at Google Scholar · View at PubMed
  5. E. Beuter, “G6PD deficiency,” Blood, vol. 84, pp. 3613–3636, 1994. View at Google Scholar
  6. J. G. McHutchison, M. P. Manns, R. S. Brown, Jr., K. R. Reddy, M. L. Shiffman, and J. B. Wong, “Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy,” American Journal of Gastroenterology, vol. 102, no. 4, pp. 880–889, 2007. View at Publisher · View at Google Scholar · View at PubMed
  7. M. D. Coleman and N. A. Coleman, “Drug-induced methaemoglobinaemia treatment issues,” Drug Safety, vol. 14, no. 6, pp. 394–405, 1996. View at Google Scholar
  8. J. S. Daly, D. E. Hultquist, and D. L. Rucknagel, “Phenazopyridine induced methaemoglobinaemia associated with decreased activity of erythrocyte cytochrome b5 reductase,” Journal of Medical Genetics, vol. 20, no. 4, pp. 307–309, 1983. View at Google Scholar
  9. K. E. Ward and M. W. McCarthy, “Dapsone-induced methemoglobinemia,” Annals of Pharmacotherapy, vol. 32, no. 5, pp. 549–553, 1998. View at Publisher · View at Google Scholar
  10. R. Ash-Bernal, R. Wise, and S. M. Wright, “Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals,” Medicine, vol. 83, no. 5, pp. 265–273, 2004. View at Publisher · View at Google Scholar
  11. J. F. Collins, “Methemoglobinemia as a complication of 20% benzocaine spray for endoscopy,” Gastroenterology, vol. 98, no. 1, pp. 211–213, 1990. View at Google Scholar
  12. M. S. Srikanth, R. Kahlstrom, K. H. Oh, S. R. Fox, E. R. Fox, and K. M. Fox, “Topical benzocaine (Hurricaine) induced methemoglobinemia during endoscopic procedures in gastric bypass patients,” Obesity Surgery, vol. 15, no. 4, pp. 584–590, 2005. View at Publisher · View at Google Scholar
  13. G. C. Kane, S. M. Hoehn, T. R. Behrenbeck, and S. L. Mulvagh, “Benzocaine-induced methemoglobinemia based on the Mayo Clinic Experience from 28, 478 transesophageal echocardiograms: incidence, outcomes, and predisposing factors,” Archives of Internal Medicine, vol. 167, no. 18, pp. 1977–1982, 2007. View at Publisher · View at Google Scholar · View at PubMed
  14. J. M. Scott and D. G. Weir, “Drug-induced megaloblastic change,” Clinics in Haematology, vol. 9, no. 3, pp. 587–606, 1980. View at Google Scholar
  15. A. Bellou, I. Aimone-Gastin, J.-D. De Korwin et al., “Cobalamin deficiency with megaloblastic anaemia in one patient under long-term omeprazole therapy,” Journal of Internal Medicine, vol. 240, no. 3, pp. 161–164, 1996. View at Google Scholar
  16. J. M. Ruscin, R. L. Page, II, and R. J. Valuck, “Vitamin B12 deficiency associated with histamine2-receptor antagonists and a proton-pump inhibitor,” Annals of Pharmacotherapy, vol. 36, no. 5, pp. 812–816, 2002. View at Google Scholar
  17. T. Alcindor and K. R. Bridges, “Sideroblastic anaemias,” British Journal of Haematology, vol. 116, no. 4, pp. 733–743, 2002. View at Publisher · View at Google Scholar
  18. R. A. Sharp, J. G. Lowe, and R. N. Johnston, “Anti-tuberculous drugs and sideroblastic anaemia,” British Journal of Clinical Practice, vol. 44, no. 12, pp. 706–707, 1990. View at Google Scholar
  19. M. C. Montpetit, J. L. Shammo, J. Loew, S. Dunlap, S. V. Pamboukian, and A. Heroux, “Sideroblastic anemia due to linezolid in a patient with a left ventricular assist device,” Journal of Heart and Lung Transplantation, vol. 23, no. 9, pp. 1119–1122, 2004. View at Publisher · View at Google Scholar · View at PubMed
  20. L. Condamine, O. Hermine, P. Alvin, M. Levine, C. Rey, and V. Courtecuisse, “Acquired sideroblastic anaemia during treatment of Wilson's disease with triethylene tetramine dihydrochloride,” British Journal of Haematology, vol. 83, no. 1, pp. 166–168, 1993. View at Google Scholar
  21. L. Kandola, A. J. Swannell, and A. Hunter, “Acquired sideroblastic anaemia associated with penicillamine therapy for rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 54, no. 6, pp. 529–530, 1995. View at Google Scholar
  22. M. Kitahara, T. M. Cosgriff, and E. Harmon, “Sideroblastic anemia as a preleukemic event in patients treated for Hodgkin's disease,” Annals of Internal Medicine, vol. 92, pp. 625–627, 1980. View at Google Scholar
  23. N. S. Young, R. T. Calado, and P. Scheinberg, “Current concepts in the pathophysiology and treatment of aplastic anemia,” Blood, vol. 108, no. 8, pp. 2509–2519, 2006. View at Publisher · View at Google Scholar · View at PubMed
  24. M. Aksoy, S. Erdem, G. Dincol, I. Bakioglu, and A. Kutlar, “Aplastic anemia due to chemicals and drugs: a study of 108 patients,” Sexually Transmitted Disease, vol. 11, pp. 347–350, 1984. View at Google Scholar
  25. R. Andrews and N. Russell, “Aplastic anemia associated with a non-steroidal anti-inflammatory drug: relapse after exposure to another such drug,” British Medical Journal, vol. 301, p. 38, 1990. View at Google Scholar
  26. M. N. Alnigenis, M. Nalcaci, Y. Pekcelen, T. Atamer, and D. Sargin, “Possible etiologic factors in 151 Turkish patients with aplastic anemia,” American Journal of Hematology, vol. 68, no. 1, pp. 60–61, 2001. View at Publisher · View at Google Scholar · View at PubMed
  27. E. Baumelou, M. Guiguet, and J. Y. Mary, “Epidemiology of aplastic anemia in France: a case-control study,” Blood, vol. 81, no. 6, pp. 1471–1478, 1993. View at Google Scholar
  28. R. Smalling, M. Foote, G. Molineux, S. J. Swanson, and S. Elliott, “Drug-induced and antibody-mediated pure red cell aplasia: a review of literature and current knowledge,” Biotechnology Annual Review, vol. 10, pp. 237–249, 2004. View at Publisher · View at Google Scholar · View at PubMed
  29. N. Tanaka, F. Ishida, and E. Tanaka, “Ribavirin-induced pure red-cell aplasia during treatment of chronic hepatitis C,” The New England Journal of Medicine, vol. 350, no. 12, pp. 1264–1265, 2004. View at Publisher · View at Google Scholar · View at PubMed
  30. N. Casadevall, J. Nataf, B. Viron et al., “Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin,” The New England Journal of Medicine, vol. 346, no. 7, pp. 469–475, 2002. View at Publisher · View at Google Scholar · View at PubMed
  31. S. A. Summers, A. Matijevic, and M. K. Almond, “Successful re-introduction of recombinant human erythropoietin following antibody induced pure red cell aplasia,” Nephrology Dialysis Transplantation, vol. 19, no. 8, pp. 2137–2139, 2004. View at Google Scholar
  32. D. Verhelst, J. Rossert, N. Casadevall, A. Kruger, K.-U. Eckardt, and I. C. Macdougall, “Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study,” The Lancet, vol. 363, no. 9423, pp. 1768–1771, 2004. View at Publisher · View at Google Scholar · View at PubMed
  33. C. L. Bennett, S. Luminari, A. R. Nissenson et al., “Pure red-cell aplasia and epoetin therapy,” The New England Journal of Medicine, vol. 351, no. 14, pp. 1403–1408, 2004. View at Publisher · View at Google Scholar · View at PubMed
  34. R. H. Aster and D. W. Bougie, “Drug-induced immune thrombocytopenia,” The New England Journal of Medicine, vol. 357, no. 6, pp. 580–587, 2007. View at Publisher · View at Google Scholar · View at PubMed
  35. G. P. Visentin and C. Y. Liu, “Drug-induced thrombocytopenia,” Hematology/Oncology Clinics of North America, vol. 21, no. 4, pp. 685–696, 2007. View at Publisher · View at Google Scholar · View at PubMed
  36. D. W. Bougie, P. R. Wilker, and R. H. Aster, “Patients with quinine-induced immune thrombocytopenia have both “drug-dependent” and “drug-specific” antibodies,” Blood, vol. 108, no. 3, pp. 922–927, 2006. View at Publisher · View at Google Scholar · View at PubMed
  37. A. von Drygalski, B. R. Curtis, D. W. Bougie et al., “Vancomycin-induced immune thrombocytopenia,” The New England Journal of Medicine, vol. 356, no. 9, pp. 904–910, 2007. View at Publisher · View at Google Scholar · View at PubMed
  38. G. M. Arepally and T. L. Ortel, “Heparin-induced thrombocytopenia,” The New England Journal of Medicine, vol. 355, no. 8, pp. 809–817, 2006. View at Publisher · View at Google Scholar · View at PubMed
  39. T. E. Wartenkin, “Heparin-induced thrombocytopenia,” Hematology/Oncology Clinics of North America, vol. 21, pp. 589–607, 2007. View at Google Scholar
  40. R. H. Aster, B. R. Curtis, and D. W. Bougie, “Thrombocytopenia resulting from sensitivity to GPIIb-IIIa inhibitors,” Seminars in Thrombosis and Hemostasis, vol. 30, no. 5, pp. 569–577, 2004. View at Publisher · View at Google Scholar · View at PubMed
  41. R. Pisoni, P. Ruggenenti, and G. Remuzzi, “Drug-induced thrombotic microangiopathy: incidence, prevention and management,” Drug Safety, vol. 24, no. 7, pp. 491–501, 2001. View at Google Scholar
  42. A. Zakarija and C. Bennett, “Drug-induced thrombotic microangiopathy,” Seminars in Thrombosis and Hemostasis, vol. 31, no. 6, pp. 681–690, 2005. View at Publisher · View at Google Scholar · View at PubMed
  43. P. J. Medina, J. M. Sipols, and J. N. George, “Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome,” Current Opinion in Hematology, vol. 8, no. 5, pp. 286–293, 2001. View at Publisher · View at Google Scholar
  44. C. L. Bennett, B. Kim, A. Zakarija et al., “Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura. A report from the SERF-TTP Research Group and the RADAR Project,” Journal of the American College of Cardiology, vol. 50, no. 12, pp. 1138–1143, 2007. View at Publisher · View at Google Scholar · View at PubMed
  45. K. Kojouri, S. K. Vesely, and J. N. George, “Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes,” Annals of Internal Medicine, vol. 135, no. 12, pp. 1047–1051, 2001. View at Google Scholar
  46. S. Tseeng and R. Arora, “Reviews: aspirin resistance: biological and clinical implications,” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 13, no. 1, pp. 5–12, 2008. View at Publisher · View at Google Scholar · View at PubMed
  47. Y.-M. P. Shen and E. P. Frenkel, “Acquired platelet dysfunction,” Hematology/Oncology Clinics of North America, vol. 21, no. 4, pp. 647–661, 2007. View at Publisher · View at Google Scholar · View at PubMed
  48. D. Mukherjee, S. E. Nissen, and E. J. Topol, “Risk of cardiovascular events associated with selective COX-2 inhibitors,” Journal of the American Medical Association, vol. 286, no. 8, pp. 954–959, 2001. View at Google Scholar
  49. P. M. Kearney, C. Baigent, J. Godwin, H. Halls, J. R. Emberson, and C. Patrono, “Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials,” British Medical Journal, vol. 332, no. 7553, pp. 1302–1305, 2006. View at Google Scholar
  50. D. J. Kerr, J. A. Dunn, M. J. Langman et al., “Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer,” The New England Journal of Medicine, vol. 357, no. 4, pp. 360–369, 2007. View at Publisher · View at Google Scholar · View at PubMed
  51. A. K. Singh, L. Szczech, K. L. Tang et al., “Correction of anemia with epoetin alfa in chronic kidney disease,” The New England Journal of Medicine, vol. 355, no. 20, pp. 2085–2098, 2006. View at Publisher · View at Google Scholar · View at PubMed
  52. J. Bohlius, J. Wilson, J. Seidenfeld et al., “Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients,” Journal of the National Cancer Institute, vol. 98, no. 10, pp. 708–714, 2006. View at Publisher · View at Google Scholar · View at PubMed
  53. J. P. Vandenbroucke, J. Rosing, K. W. M. Bloemenkamp et al., “Oral contraceptives and the risk of venous thrombosis,” The New England Journal of Medicine, vol. 344, no. 20, pp. 1527–1535, 2001. View at Publisher · View at Google Scholar
  54. M. Cushman, L. H. Kuller, R. Prentice et al., “Estrogen plus progestin and risk of venous thrombosis,” Journal of the American Medical Association, vol. 292, no. 13, pp. 1573–1580, 2004. View at Publisher · View at Google Scholar · View at PubMed
  55. V. G. Vogel, J. P. Costantino, D. L. Wickerham et al., “Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial,” Journal of the American Medical Association, vol. 295, no. 23, pp. 2727–2741, 2006. View at Publisher · View at Google Scholar · View at PubMed
  56. A. Howell, J. Cuzick, and M. Baum, “Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer,” The Lancet, vol. 365, pp. 60–62, 2005. View at Publisher · View at Google Scholar
  57. J. S. Rogers, II, A. J. Murgo, J. A. Fontana, and P. C. Raich, “Chemotherapy for breast cancer decreases plasma protein C and protein S,” Journal of Clinical Oncology, vol. 6, no. 2, pp. 276–281, 1988. View at Google Scholar
  58. T. Saphner, D. C. Tormey, and R. Gray, “Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer,” Journal of Clinical Oncology, vol. 9, no. 2, pp. 286–294, 1991. View at Google Scholar
  59. K. I. Pritchard, A. H. G. Paterson, N. A. Paul, B. Zee, S. Fine, and J. Pater, “Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer,” Journal of Clinical Oncology, vol. 14, no. 10, pp. 2731–2737, 1996. View at Google Scholar
  60. S. R. Alberts, M. Bretscher, J. C. Wiltsie, B. P. O'Neill, B. Mokri, and T. E. Witzig, “Thrombosis related to the use of L-asparaginase in adults with acute lymphoblastic leukemia: a need to consider coagulation monitoring and clotting factor replacement,” Leukemia and Lymphoma, vol. 32, no. 5-6, pp. 489–496, 1999. View at Google Scholar
  61. J. H. Payne and A. Vora, “Thrombosis and acute lymphoblastic leukaemia,” British Journal of Haematology, vol. 138, pp. 430–445, 2007. View at Google Scholar
  62. V. Caruso, L. Iacoviello, A. Di Castelnuovo et al., “Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients,” Blood, vol. 108, no. 7, pp. 2216–2222, 2006. View at Publisher · View at Google Scholar · View at PubMed
  63. A. Palumbo, S. V. Rajkumar, M. A. Dimopoulos et al., “Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma,” Leukemia, vol. 22, no. 2, pp. 414–423, 2008. View at Publisher · View at Google Scholar · View at PubMed
  64. Y. C. Chan, D. Valenti, A. O. Mansfield, and G. Stansby, “Warfarin induced skin necrosis,” British Journal of Surgery, vol. 87, no. 3, pp. 266–272, 2000. View at Publisher · View at Google Scholar · View at PubMed
  65. T. E. Warkentin, R. S. Roberts, J. Hirsh, and J. G. Kelton, “Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study,” Chest, vol. 127, no. 5, pp. 1857–1861, 2005. View at Publisher · View at Google Scholar · View at PubMed
  66. F. A. Scappaticci, J. R. Skillings, S. N. Holden et al., “Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab,” Journal of the National Cancer Institute, vol. 99, no. 16, pp. 1232–1239, 2007. View at Publisher · View at Google Scholar · View at PubMed
  67. M. Franchini, F. Capra, N. Nicolini et al., “Drug-induced anti-factor VIIII antibodies: a systematic review,” Medical Science Monitor, vol. 13, pp. 55–61, 2007. View at Publisher · View at Google Scholar · View at PubMed
  68. P. T. Otis, D. I. Feinstein, S. I. Rapaport, and M. J. Patch, “An acquired inhibitor of fibrin stabilization associated with isoniazid therapy: clinical and biochemical observations,” Blood, vol. 44, no. 6, pp. 771–781, 1974. View at Google Scholar
  69. S. Austin and H. Cohen, “Antiphospholipid syndrome,” Medicine, vol. 34, no. 11, pp. 472–475, 2006. View at Publisher · View at Google Scholar
  70. S. Clauser, A. Fischer, and L. Darnige, “Quinine-induced lupus anticoagulant, hypoprothrombinemia, and antiprothrombin antibodies,” American Journal of Hematology, vol. 82, p. 330, 2007. View at Google Scholar
  71. Y. M. Shevchuk and J. M. Conly, “Antibiotic-associated hypoprothrombinemia: a review of prospective studies, 1966–1988,” Reviews of Infectious Diseases, vol. 12, no. 6, pp. 1109–1126, 1990. View at Google Scholar
  72. B. L. Strom, R. Schinnar, G. A. Gibson, P. J. Brennan, and J. A. Berlin, “Risk of bleeding and hypoprothrombinaemia associated with NMTT side chain antibiotics: using cefoperazone as a test case,” Pharmacoepidemiology and Drug Safety, vol. 8, no. 2, pp. 81–94, 1999. View at Publisher · View at Google Scholar
  73. A. M. Holbrook, J. A. Pereira, R. Labiris et al., “Systematic overview of warfarin and its drug and food interactions,” Archives of Internal Medicine, vol. 165, no. 10, pp. 1095–1106, 2005. View at Publisher · View at Google Scholar · View at PubMed
  74. V. Bhatt and A. Saleem, “Drug-induced neutropenia—pathophysiology, clinical features, and management,” Annals of Clinical and Laboratory Science, vol. 34, no. 2, pp. 131–137, 2004. View at Google Scholar
  75. N. Tavassoli, E. Duchayne, B. Sadaba et al., “Detection and incidence of drug-induced agranulocytosis in hospital: a prospective analysis from laboratory signals,” European Journal of Clinical Pharmacology, vol. 63, no. 3, pp. 221–228, 2007. View at Publisher · View at Google Scholar · View at PubMed
  76. F. Andersohn, C. Konzen, and E. Garbe, “Systematic review: agranulocytosis induced by nonchemotherapy drugs,” Annals of Internal Medicine, vol. 146, no. 9, pp. 657–665, 2007. View at Google Scholar
  77. K. Chaiwatanatorn, N. Lee, A. Grigg, R. Filshie, and F. Firkin, “Delayed-onset neutropenia associated with rituximab therapy,” British Journal of Haematology, vol. 121, no. 6, pp. 913–918, 2003. View at Publisher · View at Google Scholar
  78. D. C. Dale, As. Fauci, D. Guerry, and S. M. Wolff, “Comparison of agents producing a neutrophilic leukocytosis in man,” Journal of Clinical Investigation, vol. 56, pp. 808–813, 1975. View at Google Scholar
  79. Y. Shoenfeld, Y. Gurewich, L. A. Gallant, and J. Pinkhas, “Prednisone-induced leukocytosis. Influence of dosage, method and duration of administration on the degree of leukocytosis,” American Journal of Medicine, vol. 71, no. 5, pp. 773–778, 1981. View at Google Scholar
  80. S. Roath, D. Choudhury, J. G. Edwards, J. L. Francis, and A. Gordon, “Neutrophil mobilization in lithium-induced neutrophilia,” Human Psychopharmacology, vol. 2, pp. 237–241, 2004. View at Google Scholar
  81. P. R. Cohen, “Sweet's syndrome—a comprehensive review of an acute febrile neutrophilic dermatosis,” Orphanet Journal of Rare Diseases, vol. 2, no. 1, p. 34, 2007. View at Publisher · View at Google Scholar · View at PubMed
  82. A. Tefferi, M. M. Patnaik, and A. Pardanani, “Eosinophilia: secondary, clonal and idiopathic,” British Journal of Haematology, vol. 133, no. 5, pp. 468–492, 2006. View at Publisher · View at Google Scholar · View at PubMed
  83. S. Tas and T. Simonart, “Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update,” Dermatology, vol. 206, no. 4, pp. 353–356, 2003. View at Publisher · View at Google Scholar · View at PubMed
  84. N. Robinson, S. Giraud, C. Saudan et al., “Erythropoietin and blood doping,” British Journal of Sports Medicine, vol. 40, pp. i30–i34, 2006. View at Publisher · View at Google Scholar · View at PubMed
  85. N. Mauritzson, M. Albin, L. Rylander et al., “Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001,” Leukemia, vol. 16, no. 12, pp. 2366–2378, 2002. View at Publisher · View at Google Scholar · View at PubMed
  86. S. M. Smith, M. M. Le Beau, D. Huo et al., “Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series,” Blood, vol. 102, no. 1, pp. 43–52, 2003. View at Publisher · View at Google Scholar · View at PubMed
  87. M. Beaumont, M. Sanz, P. M. Carli et al., “Therapy-related acute promyelocytic leukemia,” Journal of Clinical Oncology, vol. 21, no. 11, pp. 2123–2137, 2003. View at Publisher · View at Google Scholar · View at PubMed
  88. R. E. Smith, J. Bryant, A. DeCillis, and S. Anderson, “Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience,” Journal of Clinical Oncology, vol. 21, no. 7, pp. 1195–1204, 2003. View at Publisher · View at Google Scholar
  89. D. Hershman, A. I. Neugut, J. S. Jacobson et al., “Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy,” Journal of the National Cancer Institute, vol. 99, no. 3, pp. 196–205, 2007. View at Publisher · View at Google Scholar · View at PubMed
  90. D. A. Patt, Z. Duan, S. Fang, G. N. Hortobagyi, and S. H. Giordano, “Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk,” Journal of Clinical Oncology, vol. 25, no. 25, pp. 3871–3876, 2007. View at Publisher · View at Google Scholar · View at PubMed
  91. J. Pedersen-Bjergaard, M. K. Andersen, and D. H. Christiansen, “Therapy-related acute myeloid leukemia and myelodysplasia after high- dose chemotherapy and autologous stem cell transplantation,” Blood, vol. 95, no. 11, pp. 3273–3279, 2000. View at Google Scholar
  92. K. S. Baker, T. E. DeFor, L. J. Burns, N. K. C. Ramsay, J. P. Neglia, and L. L. Robison, “New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors,” Journal of Clinical Oncology, vol. 21, no. 7, pp. 1352–1358, 2003. View at Publisher · View at Google Scholar
  93. G. J. Roboz, J. M. Bennett, M. Coleman et al., “Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma,” Leukemia Research, vol. 31, no. 8, pp. 1141–1144, 2007. View at Publisher · View at Google Scholar · View at PubMed
  94. J. Lazarou, B. H. Pomeranz, and P. N. Corey, “Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies,” Journal of the American Medical Association, vol. 279, no. 15, pp. 1200–1205, 1998. View at Publisher · View at Google Scholar
  95. A. K. Jha, G. J. Kuperman, E. Rittenberg, J. M. Teich, and D. W. Bates, “Identifying hospital admissions due to adverse drug events using a computer-based monitor,” Pharmacoepidemiology and Drug Safety, vol. 10, no. 2, pp. 113–119, 2001. View at Publisher · View at Google Scholar · View at PubMed